Excessive social media use fragments attention, promotes shallow thinking, reinforces echo chambers, and weakens memory and ...

IntroductionIn December 2025, Zscaler ThreatLabz discovered a campaign linked to APT37 (also known as ScarCruft, Ruby Sleet, and Velvet Chollima), which is a DPRK-backed threat group. In this campaign ...

Magic: The Gathering ’s Teenage Mutant Ninja Turtles crossover set is almost here, celebrating more than 40 years of turtle ...

Information concerning registration for the LRA 2026 conference, which will include a keynote address by Dr. Yolanda Sealey-Ruiz, is expected to be released shortly on the Literacy Research ...

The impulse at the root is ancient and admirable. In Jewish tradition: tikkun olam—literally, repair of the world. In its kabbalistic form, it described uncovering divine sparks hidden in ordinary ...

ARK Invest's 2025 performance data has been finalized, offering a comprehensive look back at the stocks Cathie Wood ...

VectorCertain’s 55-patent ecosystem is organized in a three-layer hub-and-spoke architecture where authority flows from governance hubs down through application spokes. This structure ensures that no ...

AFX Camera Tagger automates camera metadata in DaVinci Resolve for reliable multicam sync. Free download from Art FX.

Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory ...